Dosing and uses of Molybdenum (Molypen)
Adult dosage forms and strengths
injection solution
- 25mcg/mL
RDa
Males or females: 45 mcg/day
Pregnancy: 50 mcg/day
Lactating: 50 mcg/day
Supplementation in Patients Receiving TPN
20-120 mcg/day administered in TPn
Molybdenum Deficiency from Prolonged TPN Support
163 mcg/day added to TPN for 21 days shown to be effective
Pediatric dosage forms and strengths
injection solution
- 25mcg/mL
RDa
<6 months: 2 mcg/day
6-12 months: 3 mcg/day
1-3 years: 17 mcg/day
3-8 years: 22 mcg/day
8-13 years: 34 mcg/day
>13 years: 43 mcg/day
Molybdenum (Molypen) adverse (side) effects
Frequency not defined
Gout-like symptoms (high dose)
Warnings
Contraindications
Copper deficient patients
Undiluted injection into peripheral vein (risk of infusion phlebitis)
Pregnancy and lactation
Pregnancy category: C
Lactation: Detected in milk; use caution
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Molybdenum (Molypen)
Mechanism of action
Cofactor in xanthine oxidase (uric acid formation), aldehyde oxidase (EtOH detoxification), sulfite oxidase (sulfite detoxification)
Tetrathiomolybdate complexes with copper in GI tract & blood to decrease toxicity
Pharmacokinetics
Excretion: Urine (primarily); bile (minimal)
